Sealing and Barrier Solutions with High-Performance Materials
Saint-Gobain Seals is featuring several sealing and polymer solutions at ACHEMA including the OmniSeal spring-energized seals for liquid chromatography and the Rulon wear components for pharmaceutical manufacturing equipment.
Saint-Gobain Seals is featuring several sealing and polymer solutions at ACHEMA including the OmniSeal spring-energized seals for liquid chromatography and the Rulon wear components for pharmaceutical manufacturing equipment.
OmniSeal is a high-performance spring-energized polymer seal capable of handling extreme service conditions. It is typically used where ultra-low friction, chemical compatibility, and extreme temperature are required.
The Rulon material is a family of proprietary, homogeneous materials mostly of PTFE based resins, engineered and developed with specific custom applications in mind. It includes a variety of high-performance bearings and components, which meet today's need for enhanced wear performance in a PTFE-based material. The Rulon material withstands a variety of harsh environments such as extreme dryness, cryogenic temperatures, water, steam, and hydrocarbon fuel.
Source: Saint-Gobain Seals, Hall 9.0, Stand B62
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
